Bedside-to-bench pharmacology: A complementary concept to translational pharmacology

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 6, 2010, Pages 647-649

  Lotsch J ^a   Geisslinger, G ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PHARMACOLOGY; DRUG RESEARCH; HUMAN; LOGIC; MEDICAL SPECIALIST; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SHORT SURVEY; TRANSLATIONAL PHARMACOLOGY;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; LOGIC; MODELS, ORGANIZATIONAL; PHARMACOLOGY, CLINICAL; TRANSLATIONAL RESEARCH;

EID: 77952574676     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.18     Document Type: Short Survey

References (9)

1. Anger, G.J. & Piquette-Miller, M. Translational pharmacology: harnessing increased specialization of research within the basic biological sciences. Clin. Pharmacol. Ther. 83, 797-801 (2008).
2. Quinn, S. & Markovits, H. Conditional reasoning, causality, and the structure of semantic memory: strength of association as a predictive factor for content effects. Cognition 68, B93-B101 (1998).
3. Mayer, M.C. & Pirri, F. First order abduction via tableau and sequent calculi. Log. J. IGPL 1, 99-117 (1993).
4. Harman, G.H. The inference to the best explanation. Philos. Rev. 74, 88-95 (1965).
5. Nishizawa, D. et al. Association between KCNJ6 (GIRK2) gene polymorphisms and postoperative analgesic requirements after major abdominal surgery. PloS One 4, e7060 (2009).
6. Lötsch, J, Prüss, H, Veh, RW & Doehring A. A KCNJ6 (GIRK2) gene polymorphism modulates opioid actions on addiction and pain but not on pupil size. Pharmacogenet. Genomics (2010); e-pub ahead of print 9 March 2010.
7. Doehring, A. et al. Cross-sectional assessment of the consequences of a GTP cyclohydrolase 1 haplotype for specialized tertiary outpatient pain care. Clin. J. Pain 25, 781-785 (2009).
8. Lötsch, J., Klepstad, P., Doehring, A. & Dale, O. A GTP cyclohydrolase 1 genetic variant delays cancer pain. Pain 148, 103-106 (2009).
9. Lötsch, J., Sperker, B., Kroemer, H.K. & Geisslinger, G. Verapamil decreases glucuronidase activity in the gut. Biochem. Pharmacol. 63, 1575-1578 (2002).